Phathom Pharmaceuticals (PHAT) Current Leases (2019 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Current Leases of $670000.0 for Q2 2026, up 181.51% year-over-year from $238000.0 in Q2 2025, and little changed quarter-over-quarter from $667000.0 in Q1 2026.
Phathom Pharmaceuticals (PHAT) Current Leases (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Current Leases for 8 consecutive years, with $670000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Leases rose 181.51% year-over-year to $670000.0; the TTM figure through Jun 2026 stood at $670000.0 (up 181.51% YoY), while the FY2025 annual figure was $648000.0, up 29.34% from the prior year.
- Current Leases steadied at $670000.0 in Q2 2026 per PHAT's latest filing, from $667000.0 in the prior quarter.
- Across five years, Current Leases topped out at $730000.0 in Q1 2024 and bottomed at $238000.0 in Q2 2025.
- Historically, Current Leases has averaged $619333.3 across 5 years, with a median of $675000.0 in 2024.
- Annual changes were most pronounced in 2025 — Current Leases slumped 66.94% — and 2026, when it jumped 181.51%.
- Phathom Pharmaceuticals' Current Leases stood at $708000.0 in 2022, then climbed by 2.54% to $726000.0 in 2023, then tumbled by 30.99% to $501000.0 in 2024, then advanced by 29.34% to $648000.0 in 2025, then grew by 3.4% to $670000.0 in 2026.
- Business Quant data shows PHAT's Current Leases at $670000.0 in Q2 2026, $667000.0 in Q1 2026, and $648000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | 670,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 670,000.00 |
| Mar 31, 2026 | 667,000.00 |
| Dec 31, 2025 | 648,000.00 |
| Sep 30, 2025 | 591,000.00 |
| Jun 30, 2025 | 238,000.00 |
| Mar 31, 2025 | 316,000.00 |
| Dec 31, 2024 | 501,000.00 |
| Sep 30, 2024 | 680,000.00 |
| Jun 30, 2024 | 720,000.00 |
| Mar 31, 2024 | 730,000.00 |
| Dec 31, 2023 | 726,000.00 |
| Sep 30, 2023 | 721,000.00 |
| Jun 30, 2023 | 717,000.00 |
| Mar 31, 2023 | 712,000.00 |
| Dec 31, 2022 | 708,000.00 |
| Sep 30, 2022 | 685,000.00 |
| Jun 30, 2022 | 628,000.00 |
| Mar 31, 2022 | 490,000.00 |
| Dec 31, 2021 | 487,000.00 |
| Sep 30, 2021 | 484,000.00 |